How should we analyse FDG PET studies for monitoring tumour response?
How should we analyse FDG PET studies for monitoring tumour response?
复制标题
DOI：
10.1007/s00259-006-0131-5
复制
发表时间：
2006-07-01
影响因子：
9.1
通讯作者：
Hoekstra, Otto S.
中科院分区：
文献类型：
--
作者：
Lammertsma, Adriaan A.;Hoekstra, Corneline J.;Hoekstra, Otto S.
FDGPET是一种在抗癌治疗早期监测肿瘤反应的有前景的技术。然而，由于目前使用的方法繁多，进展有限。在这里，简要讨论了多中心试验中最有希望的技术，并强调了标准化的必要性。此外，还提出了一种使用新药进行反应监测研究的方法。这种方法利用了反应监测研究的大型数据库，该数据库定义了简化的临床方法与经典细胞毒药物的全面定量分析之间的关系。对于一种新药，首先进行一项先导性研究，以评估它是否影响这种关系。基于这一试点，决定是否可以在进一步的研究中使用简化的临床方法。
FDG PET is a promising technique for monitoring tumour response early during anticancer therapy. Progress, however, has been limited owing to the multitude of methods currently in use. Here, the most promising techniques for multi-centre trials are discussed briefly, with emphasis on the need for standardisation. In addition, an approach is presented for response monitoring studies using newly developed drugs. This approach makes use of a large database of response monitoring studies, which defines the relationship between simplified clinical methods and full quantitative analysis for classic cytotoxic drugs. For a new drug, first a pilot study is performed to assess whether it affects this relationship. Based on this pilot, it is decided whether or not a simplified clinical method can be used in further studies.